Valuation: Apogee Therapeutics, Inc.

Market Cap 10.05B 8.78B 8.1B 7.47B 14.08B 968B 14.39B 96.86B 38.1B 474B 37.74B 36.91B 1,632B P/E 2026 *
-31.1x
P/E 2027 * -24x
Enterprise Value 9.07B 7.93B 7.31B 6.74B 12.71B 873B 12.99B 87.42B 34.38B 428B 34.06B 33.31B 1,473B EV / Sales 2026 *
998x
EV / Sales 2027 * 745x
Free-Float
94.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day-0.06%
1 week+0.27%
Current month+0.97%
1 month+51.55%
3 months+45.35%
6 months+63.35%
Current year+77.55%
1 week 133.54
Extreme 133.54
134.32
1 month 87.4
Extreme 87.4
134.32
Current year 60.35
Extreme 60.35
134.32
1 year 34.34
Extreme 34.34
134.32
3 years 14.19
Extreme 14.19
134.32
5 years 14.19
Extreme 14.19
134.32
10 years 14.19
Extreme 14.19
134.32
Manager TitleAgeSince
Chief Executive Officer 36 31/08/2022
Director of Finance/CFO 60 31/12/2022
Chief Tech/Sci/R&D Officer - 30/04/2023
Director TitleAgeSince
Director/Board Member 54 21/06/2023
Director/Board Member 62 31/05/2023
Director/Board Member 36 31/05/2023
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Don

Chief Executive Officer

-75,046 0.1340%
01/07/26 Fiscal year

Chief Technology Officer

13,750 0.0246%
22/06/26 Sell

Chief Executive Officer

-80,000 0.1429%
Change 5-day change 1-year change 3-year change Capi.($)
-0.06%+0.27%+243.63%+544.30% 10.05B
-1.29%-3.11%-0.39%+4.92% 49.7B
+2.90%-1.28%+372.45%+593.31% 38.09B
-1.47%+4.39%+7.39%+57.55% 35.29B
-1.92%-0.77%+26.33%-6.83% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
+0.97%-2.61% - - 16.14B
+0.05%-0.15%+68.39%+117.27% 15.36B
+1.12%+1.91%+15.90%+19.65% 13.89B
+0.97%+2.15%+16.64%-30.08% 13.02B
Average +0.08%-0.47%+83.86%+147.50% 25.39B
Weighted average by Cap. -0.20%-0.60%+81.64%+136.84%

Financials

2026 *2027 *
Net sales 9.09M 7.94M 7.33M 6.76M 12.74M 875M 13.02M 87.62M 34.46M 429M 34.14M 33.39M 1.48B 12.5M 10.92M 10.08M 9.29M 17.51M 1.2B 17.9M 120M 47.39M 590M 46.94M 45.91M 2.03B
Net income -318M -277M -256M -236M -445M -30.58B -455M -3.06B -1.2B -14.98B -1.19B -1.17B -51.55B -416M -364M -336M -310M -583M -40.1B -596M -4.01B -1.58B -19.64B -1.56B -1.53B -67.61B
Net Debt -980M -856M -790M -728M -1.37B -94.33B -1.4B -9.44B -3.71B -46.2B -3.68B -3.6B -159B -740M -647M -597M -550M -1.04B -71.28B -1.06B -7.13B -2.81B -34.91B -2.78B -2.72B -120B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
17/07/26 US$134.00 -0.06% 1,352,049
16/07/26 US$134.08 -0.16% 1,359,089
15/07/26 US$134.29 +0.25% 607,392
14/07/26 US$133.96 +0.10% 1,365,160
13/07/26 US$133.82 +0.13% 1,009,120
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
134.08USD
Average target price
130.53USD
Spread / Average Target
-2.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock